Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087639 | 0.79 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL3089908 | 0.79 | PDE4B (0.48) | HRH3PDE4BHRH1 | |
| SCHEMBL3100519 | 0.72 | HRH3 (0.61) | HRH3FFAR4 | |
| SCHEMBL3090791 | 0.71 | HRH3 (0.61) | HRH3HRH1 | |
| SCHEMBL3087258 | 0.71 | HRH3 (0.56) | HRH3HRH1 | |
| SCHEMBL3098285 | 0.71 | HRH3 (0.43) | HRH3HRH1 | |
| SCHEMBL3094879 | 0.70 | HRH3 (0.58) | HRH3HRH1 | |
| SCHEMBL3100797 | 0.70 | HRH3 (0.49) | HRH3HRH1 | |
| SCHEMBL3094146 | 0.70 | HRH3 (0.39) | HRH3PPARGHRH1 | |
| SCHEMBL3089314 | 0.69 | KMT2A (0.42) | HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | claimed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | claimed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | HRH3 211/4885LMNA 933/4885PDE4B 2377/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885LMNA 1097/4885PDE4B 1098/4885 |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885LMNA 1097/4885PDE4B 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.